The title of Fellow of the American Society of Clinical Oncology (FASCO) is one of the highest honors conferred by the American Society of Clinical Oncology (ASCO). Introduced in 2007, this distinction is awarded annually to a select group of ASCO members who have demonstrated outstanding volunteer service, leadership, and commitment to ASCO’s mission.
Unlike awards based solely on academic or clinical achievements, FASCO is reserved for individuals who have made sustained, meaningful contributions to the oncology community through active involvement in ASCO programs, committees, publications, policy, and mentorship initiatives.
FASCO as a Symbol of Influence and Trust
Unlike awards focused purely on academic or clinical distinction, FASCO emphasizes organizational and community-oriented leadership. Recipients serve as trusted ambassadors for ASCO’s values shaping programs, influencing policy, and supporting the growth of the oncology workforce globally.
The 100 individuals honored in 2025 embody the critical link between clinical excellence and professional service. Their collective work reinforces ASCO’s global influence through mentorship, guideline development, educational leadership, and patient-centered advocacy.
FASCO 2025 Recipients
| Images | Name |
|---|---|
 | Janet Abrahm, MD, FAAHPM, FACP, FASCO A Professor of Medicine at Harvard Medical School and Institute Physician at Dana‑Farber/Brigham & Women’s, Dr. Abrahm pioneered outpatient and inpatient palliative care services and launched a fellowship program in 2001. She has authored multiple leading books and over 150 papers on supportive oncology and was awarded ASCO’s Walther Cancer Foundation Supportive Oncology Award in 2024. Her leadership in patient-centered symptom management has shaped national palliative care education programs. |
 | Himisha Beltran, MD, FASCO Specializing in advanced prostate cancer, Dr. Beltran focuses on molecular mechanisms of resistance and neuroendocrine transformation. Her translational research has shaped emerging precision medicine strategies and gained recognition at national conferences. |
 | Nishin Bhadkamkar, MD, FASCO A seasoned gastrointestinal oncologist, Dr. Bhadkamkar has led multiple trials in colorectal cancer and contributed to national guidelines. He is a distinguished educator and long-time author in the field of translational oncology. |
 | Kathleen E. Bickel, MD, FACP, MPhil, FASCO Dr. Bickel practices thoracic oncology and is board-certified in internal medicine and palliative care. She co-developed national guidance on integrating supportive care into oncology and is known for her leadership in quality and education. |
 | Maria T. Bourlon, MD, MSc, FASCO As a medical oncologist in Mexico, Dr. Bourlon established her country’s first urologic oncology clinic and advances clinical research in cervical, bladder, and kidney cancers. She mentors early-career oncologists throughout Latin America and champions equitable access to care. |
 | Sam Brondfield, MD, MA, FASCO A lung and head-and-neck cancer specialist and educator, Dr. Brondfield is known for integrating teaching innovations into clinical care. He oversees hospital-based oncology consult services and develops novel educational programs for trainees. |
 | Mehmet Copur, MD, FACP, FASCO Dr. Copur is a longtime medical oncologist with expertise in endocrine and pediatric cancers. Known for international collaborations, he has led cross-disciplinary trials and promoted comprehensive care through decades of mentoring and leadership. |
 | Robert M. Daly, MD, MBA, FASCO This physician leader combines clinical thoracic oncology with health systems innovation, leveraging his MD and MBA background. His work centers on improving treatment delivery and patient access through digital and integrated care models. |
 | Rebecca Dent, MD, FASCO Dr. Dent is a breast and gynecologic oncology specialist whose research and clinical practice enhance outcomes in early-stage disease. As an educator and advocate, she promotes awareness and quality care in women’s cancers. |
 | Aakash Desai, MD, MPH, FASCO A clinician–scientist with expertise in gastrointestinal oncology and global health, Dr. Desai leads trials across continents and invests deeply in education and mentorship for physicians in resource-limited settings. |
 | Shirish M. Gadgeel, MD, FASCO Dr. Gadgeel is a thoracic oncologist with emphasis on immunotherapies for lung cancer. He drives clinical trials, leads multidisciplinary tumor boards, and is recognized for bridging research and patient care. |
 | Sanjay Goel, MD, MS, FASCO Specializing in gastrointestinal oncology, Dr. Goel focuses on colorectal and pancreatic cancer research, particularly in molecularly stratified trials. He is a respected teacher and institutional leader in oncology education. |
 | Michael S. Gordon, MD, FASCO A breast cancer expert, Dr. Gordon has actively contributed to early-phase clinical trials and cancer drug development. His leadership in trial design and translational research is widely recognized. |
 | Sharad Goyal, MD, MS, FASTRO, FASCO |
 | Stacy W. Gray, MD, FASCO Dr. Gray’s work spans service delivery, health policy, and patient engagement. She leads research on decision-making in oncology and has shaped national guidelines for care in diverse populations. |
 | Petros Grivas, MD, PhD, FASCO A genitourinary medical oncologist, Dr. Grivas conducts pivotal research in bladder and prostate cancer trials. He balances laboratory and clinical leadership and is a prolific mentor in translational medicine. |
 | Arjun Gupta, MD, FASCO Dr. Gupta specializes in head-and-neck and gastrointestinal oncology, contributing to early clinical trials and diagnostics. He is recognized for combining educational activities with patient-centered clinical work. |
 | Shilpi Gupta, MD, FASCO Dr. Gupta directs research and care in pancreas and hepatobiliary cancers. She leads innovative trial designs and advocates for equitable clinical trial access and patient education. |
 | Jack Hensold, MD, FASCO A genitourinary oncologist, Dr. Hensold supports practice innovation in kidney and urologic cancers. He is known for mentorship in both clinical and academic oncology settings. |
 | Claudine Isaacs, MD, FRCPC, FASCO Dr. Isaacs is a global oncology leader working across breast cancer control, policy, and education. She has contributed to international cancer guidelines and champions disparities research and equity. |
 | Steve Lee, MD, FACP, FASCO A physician-scientist in medical oncology, Dr. Lee’s focus is on translational discoveries in colorectal cancer. He combines clinical care with efforts to expand research infrastructure and education in GI oncology. |
 | Inga T. Lennes, MD, MPH, MBA, FASCO Dr. Lennes blends oncology, public health, and health policy, working to advance cancer care equity. She leads quality improvement and advocacy programs within academic cancer centers. |
 | Sagar Lonial, MD, FACP, FASCO A global leader in multiple myeloma, Dr. Lonial has shaped treatment paradigms through academic and cooperative group trials. He is highly regarded as a mentor to trainees and peers in hematologic oncology. |
 | Alison W. Loren, MD, MSCE, MS, FACP, FASCO Dr. Loren is a gynecologic oncology specialist with expertise in clinical trial design, outcomes research, and cancer prevention. She serves in leadership roles and mentors across clinical and research domains. |
 | Issam Makhoul, MD, FASCO An expert in genitourinary malignancies, Dr. Makhoul leads molecularly informed clinical trials and translational research in advanced urothelial and prostate cancers. |
 | Heather L. McArthur, MD, MPH, FASCO Dr. McArthur is a breast oncologist focusing on novel endocrine therapies and survivorship. She leads collaborative research efforts on adjuvant treatment optimization and patient-reported outcomes. |
 | Paul L. Nguyen, MD, MBA, FASCO Dr. Nguyen combines cardiology and oncology training in cardio-oncology work and breast cancer treatment trials. He is recognized for leadership in survivorship care and multidisciplinary care models. |
 | Ryan D. Nipp, MD, FASCO A palliative oncology specialist, Dr. Nipp advances research on quality of life and supportive care interventions. He is a leader in integrating serious illness communication training into oncology fellowship programs. |
 | Amy C. Peterson, MD, FASCO Dr. Peterson is a thoracic oncologist known for her leadership in patient advocacy and clinical trials design. She mentors trainees in advanced therapies and personalized oncology. |
 | Tycel J. Phillips, MD, FASCO A leukemia expert, Dr. Phillips has led pivotal clinical trials and translational investigations in hematologic malignancies. He is recognized for developing novel targeted treatment protocols. |
 | Deepa Rangachari, MD, FASCO Dr. Rangachari specializes in thoracic oncology and molecular therapeutics. She leads research on targeted and immune-based treatments and is a sought-after speaker at major oncology meetings. |
 | Mina S. Sedrak, MD, MS, FASCO An oncogeriatric specialist, Dr. Sedrak develops care strategies for older adults with cancer. She leads programs in survivorship and functional assessment in geriatric oncology. |
 | Lesley K. Seymour, MD, PhD, FASCO A public health-oriented oncologist, Dr. Seymour works on tobacco control, survivorship, and health systems. Her leadership spans research, teaching, and global cancer control initiatives. |
 | Surendranath S. Shastri, MD, DPH, FASCO Dr. Shastri is a leader in global oncology, public health, and cervical cancer prevention. He has conducted large-scale screening programs and shaped regional cancer policy frameworks. |
 | Joseph A. Sparano, MD, FACP, FASCO A breast cancer medical oncologist, Dr. Sparano directs clinical research to improve outcomes in metastatic and early-stage disease. He has led trials that shaped modern treatment guidelines. |
 | Tom Stinchcombe, MD, FASCO Dr. Stinchcombe specializes in lung cancer clinical trials and multidisciplinary care innovations. He has held leadership roles in cooperative oncology organizations and mentorship programs. |
 | Erica M. Stringer‑Reasor, MD, FASCO Dr. Stringer‑Reasor is a lung cancer expert with a focus on precision medicine. She integrates genomic profiling into clinical decision-making and advocates for trial access in underrepresented communities. |
 | Jason Westin, MD, MS, FACP, FASCO Dr. Westin leads gastrointestinal cancer research, with a focus on early-phase trials and biomarker-driven therapies. He is known for combining laboratory science with patient care in translational oncology. |
 | Robert A. Wolff, MD, FASCO A pancreatic and GI cancer specialist, Dr. Wolff has led multicenter clinical trials and contributed extensively to treatment guidelines. His contributions span patient care, education, and international research collaborations. |
 | Yun Yen, MD, PhD, FACP, FASCO Dr. Yen is an academic oncologist focusing on solid tumors and survivorship. His work integrates clinical care with translational research and leadership in multidisciplinary oncology teams. |
 | Gabriel A. Brooks, MD, MPH, FASCO Dr. Brooks, based at Dartmouth Cancer Center, is a leading expert in quality, safety, and value of cancer care delivery. His research on end-of-life care and patient experience informs national policy and supports a more humanistic approach to oncology. |
 | Alexander Dimitrios Colevas, MD, BA, FASCO An expert in head and neck cancers at Stanford, Dr. Colevas leads innovative early-phase trials and is a champion of collaborative science through cooperative groups. His mentorship has shaped many careers in academic oncology. |
 | Ibiayi Dagogo-Jack, MD, FASCO A thoracic oncologist at Mass General Cancer Center, Dr. Dagogo-Jack’s research focuses on resistance mechanisms in lung cancer. She is a rising leader in precision oncology and a powerful voice for diversity in cancer research. |
 | Devika Govind Das, MD, MBBS, MS, FASCO Dr. Das is a palliative care oncologist recognized for her work integrating palliative care into standard oncology practice. Through clinical care, research, and education, she promotes quality of life and compassionate communication for patients with advanced cancer. |
 | Jonathan W. Friedberg, MD, FASCO As Director of the Wilmot Cancer Institute at the University of Rochester, Dr. Friedberg is a prominent lymphoma expert. His clinical trials and translational work have improved therapeutic approaches in indolent and aggressive lymphomas. |
 | Ramaswamy Govindan, MD, FASCO A world-renowned lung cancer researcher at Washington University, Dr. Govindan’s work on genomics and immunotherapy has changed the landscape of thoracic oncology. He is a key thought leader and educator in the global oncology community. |
| Images | Name |
|---|---|
 | Erika P. Hamilton, MD, FASCO Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Dr. Hamilton has led pivotal clinical trials in targeted therapies and immunotherapy for breast and ovarian cancers. She is a nationally recognized advocate for expanding access to cutting-edge therapies and precision oncology. Her work has directly influenced treatment paradigms and improved outcomes for patients with metastatic breast cancer. |
 | David N. Hayes, MD, MPH, FASCO Professor of Medicine at Duke University School of Medicine and a leading translational researcher in head and neck cancers, Dr. Hayes has made key contributions to the integration of genomics in clinical decision-making. He co-led trials that defined molecular classifications of head and neck squamous cell carcinomas and their implications in therapy response and resistance. His mentorship has shaped the next generation of clinician-scientists in oncology. |
 | Leslie J. Hinyard, PhD, MSW, FASCO Executive Director of the Center for Health Outcomes Research at Saint Louis University, Dr. Hinyard has led groundbreaking work on cancer disparities, health literacy, and patient-reported outcomes. With a unique background in social work and public health, she has pioneered strategies to reduce inequities in cancer care delivery and survivorship. Her research has been instrumental in shaping policy around equity-focused care. |
 | Richard T. Hoppe, MD, FASCO Professor Emeritus at Stanford University School of Medicine, Dr. Hoppe is a legendary figure in radiation oncology and lymphoma research. A pioneer in the use of advanced radiation techniques for Hodgkin lymphoma, he helped establish the modern standards for staging and combined-modality therapy. His decades-long career includes leadership roles in national cooperative groups and a lasting legacy of clinical excellence and mentorship. |
 | Yelena Y. Janjigian, MD, FASCO Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, Dr. Janjigian is a global authority on gastroesophageal cancers. She led practice-changing trials in HER2-positive and PD-L1-positive gastric cancer and helped redefine biomarker-driven treatment. Her visionary research has transformed the management of upper GI cancers and made her a sought-after speaker and collaborator internationally. |
 | Komal L. Jhaveri, MD, FACP, FASCO A breast and early drug development specialist at Memorial Sloan Kettering Cancer Center, Dr. Jhaveri is recognized for her work in HER2-low and endocrine-resistant breast cancers. She has been at the forefront of trials integrating novel ADCs and CDK4/6 inhibitors, contributing to new standards of care. She is also a strong advocate for mentorship and diversity in clinical oncology leadership. |
 | Robin Lewis Jones, MD, MBBS, BSc, MRCP, FASCO Leader of the Sarcoma Unit at The Royal Marsden NHS Foundation Trust and Professor of Medical Oncology at the Institute of Cancer Research, London, Dr. Jones is internationally known for his work in sarcoma clinical trials and translational research. His leadership has been key in bringing innovative therapies to rare and complex soft tissue sarcomas, significantly expanding treatment options for patients worldwide. |
 | William Kevin Kelly, DO, FASCO Professor of Medical Oncology at Thomas Jefferson University, Dr. Kelly is a renowned genitourinary cancer expert, known for his leadership in prostate and bladder cancer research. His role in developing docetaxel-based regimens and novel androgen-targeted therapies has made a lasting impact on the field. He has also served in multiple advisory and leadership positions across cooperative groups and professional societies. |
 | Abhishek Kumar, MBBS, FASCO A dedicated oncologist and researcher, Dr. Kumar has contributed significantly to global oncology efforts, particularly in expanding access to clinical trials and evidence-based cancer care in low-resource settings. His advocacy for equitable care delivery, combined with his clinical excellence, has earned him recognition as an emerging leader committed to transforming global oncology landscapes. |
 | Lisa Y. Law, MD, FASCO An esteemed hematologist-oncologist at Kaiser Permanente, Dr. Law has made vital contributions to improving community oncology practices, particularly in supportive care and quality improvement. She has championed patient-centered models and played a pivotal role in implementing evidence-based guidelines within integrated healthcare systems, enhancing cancer outcomes across diverse populations. |
 | Andrew B. Lassman, MD, FASCO Chief of Neuro-Oncology at Columbia University Irving Medical Center, Dr. Lassman is a prominent figure in glioma research. He has led trials investigating temozolomide, targeted agents, and novel radiotherapeutic strategies in glioblastoma. As a mentor and educator, he has shaped neuro-oncology training and has been instrumental in developing guidelines and standards of care in CNS malignancies. |
 | Georgina V. Long, MD, PhD, FRACP, FASCO Co-Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at the University of Sydney, Professor Long is globally recognized for her landmark work in immunotherapy and targeted therapy in melanoma. Her leadership in clinical trials has transformed melanoma from a once-fatal disease into a highly treatable condition. She has received international accolades for her scientific excellence and patient advocacy. |
 | Martina Cathryn Murphy, MD, FASCO A gastrointestinal oncologist at the University of Florida, Dr. Murphy has distinguished herself through her dedication to patient care, education, and health equity. She has led initiatives aimed at improving access to guideline-concordant care in underserved populations and is actively involved in efforts to enhance diversity and inclusion in oncology. |
 | Deirdre O'Mahony, MD, FASCO Consultant Medical Oncologist at Galway University Hospital in Ireland, Dr. O'Mahony has been a leader in breast cancer research and clinical trials across Europe. She has contributed extensively to collaborative research networks and is known for her advocacy in integrating novel agents into routine care. Her clinical excellence and mentorship have strengthened oncology practice across Ireland. |
 | Martin Palmeri, MD, MBA, FASCO Director of the Cancer Center at Prisma Health in South Carolina, Dr. Palmeri is a dedicated oncologist and administrator who has led innovative quality improvement initiatives in cancer care delivery. His work spans both clinical excellence in gastrointestinal oncology and strategic leadership in expanding access to oncology services in community settings. |
 | Alberto S. Pappo, MD, FASCO Director of the Solid Tumor Division at St. Jude Children's Research Hospital, Dr. Pappo is a world-renowned leader in pediatric oncology and sarcoma research. He has been instrumental in developing new treatment protocols for rhabdomyosarcoma and rare pediatric solid tumors, significantly improving survival rates. His lifelong commitment to children with cancer is widely recognized and honored globally. |
 | Electra D. Paskett, PhD, MSPH, FASCO Director of the Division of Cancer Prevention and Control at The Ohio State University, Dr. Paskett is a preeminent cancer epidemiologist known for her work in cancer disparities, rural health, and community-based interventions. She has led major national studies aimed at increasing screening and prevention efforts among underserved groups. Her research has shaped public health policies and equity-focused cancer care. |
 | Dionisia Marie Quiroga, DO, PhD, FASCO A physician-scientist at the University of Texas MD Anderson Cancer Center, Dr. Quiroga is recognized for her contributions to precision oncology and translational research in breast cancer. Her dual training in clinical medicine and molecular biology has enabled her to lead research integrating genomic insights into patient care. She is also a passionate mentor and advocate for women in science and oncology. |
 | Kavitha Ramchandran, MD, FASCO Clinical Associate Professor of Medicine at Stanford University and Associate Division Chief of Medical Oncology, Dr. Ramchandran has advanced the field of thoracic oncology and health equity. Her work focuses on improving access to cancer clinical trials and incorporating patient-reported outcomes into lung cancer treatment. She is a leader in promoting inclusive care models across academic and community practices. |
 | Evangelia Razis, MD, PhD, FASCO Director of the Oncology Department at Hygeia Hospital in Athens, Greece, Dr. Razis is a prominent figure in global oncology and translational research. She has led major efforts to bridge molecular diagnostics with real-world care in breast and lung cancers, and her commitment to expanding research infrastructure in Europe has helped shape modern oncology in the region. |
 | Richard F. Riedel, MD, FASCO A medical oncologist at Duke Cancer Institute, Dr. Riedel is known for his leadership in sarcoma research and compassionate patient care. He has contributed to the development of targeted therapies and immunotherapies for soft tissue and bone sarcomas and has been a dedicated mentor and educator for early-career oncologists in rare cancers. |
 | Nicholas J. Robert, MD, FASCO Medical Director at US Oncology Research, Dr. Robert has played a critical role in bringing clinical trials to community oncology settings. He has led numerous multicenter studies in breast and lung cancer, helping to accelerate drug development and expand access to cutting-edge treatments for patients outside academic centers. His research and leadership have had lasting national impact. |
 | Tracy L. Rose, MD, FASCO A genitourinary oncologist at the University of North Carolina Lineberger Comprehensive Cancer Center, Dr. Rose is recognized for her work in clinical trials and drug development in bladder and kidney cancers. Her focus on patient-centric trial design and inclusion has led to improved therapeutic options and a more equitable research landscape. |
 | Abby R. Rosenberg, MD, MS, MA, FAAP, FAAHPM, FASCO Chief of Pediatric Palliative Care at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Dr. Rosenberg is a national leader in adolescent and young adult (AYA) oncology and resilience research. Her work on emotional well-being, communication, and psychosocial support has transformed standards in holistic cancer care for young patients and their families. |
 | Lori J. Rosenstein, MD, FASCO Hematologist-oncologist at Gundersen Health System, Dr. Rosenstein is recognized for her dedication to patient care in rural and community oncology. A champion of clinical excellence in underserved areas, she has led quality improvement projects that emphasize personalized treatment approaches and evidence-based care delivery in non-academic settings. |
 | Nita Louise Seibel, MD, FASCO Former Head of the Pediatric Solid Tumor Therapeutics Program at the National Cancer Institute, Dr. Seibel has been a trailblazer in pediatric oncology drug development. She played a pivotal role in launching and overseeing clinical trials for rare pediatric tumors, and her legacy includes the advancement of safer, more effective therapies for children and adolescents with cancer. |
 | Priyanka Sharma, MD, FASCO Professor of Medicine at the University of Kansas Medical Center and a leading breast cancer researcher, Dr. Sharma is best known for her work in triple-negative breast cancer and cancer genomics. Her leadership in biomarker-driven therapy development has helped tailor treatments for aggressive breast cancer subtypes. She also plays an active role in mentoring physician-scientists and promoting diversity in oncology research. |
 | Heloisa P. Soares, MD, FASCO Associate Professor at the University of Utah Huntsman Cancer Institute, Dr. Soares is a leading expert in neuroendocrine and gastrointestinal cancers. Her research has focused on rare tumors and clinical trial development, helping expand treatment options for patients with limited standard therapies. She is also a strong advocate for global oncology collaboration and mentorship in underrepresented groups. |
 | Walter Stadler, MD, FASCO Dean for Clinical Research and Fred C. Buffett Professor at the University of Chicago, Dr. Stadler is a renowned leader in genitourinary oncology. He has played a central role in advancing systemic therapies for kidney, bladder, and prostate cancers. A prolific investigator and mentor, Dr. Stadler has contributed to shaping both the science and structure of modern oncology clinical research. |
 | Latha Subramanian, MBChB, FASCO A dedicated oncologist at Minnesota Oncology, Dr. Subramanian has championed high-quality, compassionate care in community oncology settings. She has been instrumental in integrating evidence-based guidelines into routine practice and enhancing clinical trial access for patients in suburban and rural communities. Her leadership exemplifies the bridge between research and real-world care. |
 | Olatunji B. Alese, MD, FWACS, FASCO A gastrointestinal oncologist at Winship Cancer Institute of Emory University, Dr. Alese is recognized for his contributions to clinical trials in gastrointestinal malignancies and dedication to improving outcomes for underserved populations through patient-centered care and mentorship. |
 | Andrea B. Apolo, MD, FASCO As a senior investigator at the NCI and head of the bladder cancer section, Dr. Apolo has led pivotal trials in bladder and rare genitourinary cancers, advancing immunotherapy and targeted therapy in the field. She is a leading advocate for inclusion in oncology research. |
 | Mark A. Applebaum, MD, FASCO A pediatric oncologist at the University of Chicago, Dr. Applebaum specializes in neuroblastoma. His research integrates genomics and precision medicine to improve outcomes in childhood cancers, while he actively mentors the next generation of physician-scientists. |
 | Julie E. Bauman, MD, MPH, FASCO Dr. Bauman, Deputy Director of the GW Cancer Center, is a national leader in head and neck cancer and chemoprevention. Her work bridges translational science and clinical trials, and she is deeply committed to health equity and access to care. |
 | Sibel Blau, MD, FASCO A community oncologist and president of the Quality Cancer Care Alliance Network, Dr. Blau champions innovation in community oncology, real-world data research, and value-based care models, while mentoring women leaders in medicine.A community oncologist and president of the Quality Cancer Care Alliance Network, Dr. Blau champions innovation in community oncology, real-world data research, and value-based care models, while mentoring women leaders in medicine. |
 | Kristen A. Marrone, MD, FASCO A thoracic oncologist and clinical investigator at Johns Hopkins University, Dr. Marrone has led innovative research in lung cancer immunotherapy and biomarker development. She has played a key role in refining checkpoint inhibitor strategies and exploring resistance mechanisms. Her commitment to translational research continues to bridge laboratory discoveries with real-world patient care. |
 | Bradley Alexander McGregor, MD, FASCO A genitourinary oncology expert at Dana-Farber Cancer Institute and Harvard Medical School, Dr. McGregor has advanced the treatment landscape of kidney and bladder cancers through his work in immuno-oncology and targeted therapy trials. His collaborative research has shaped clinical decision-making in metastatic renal cell carcinoma and upper tract urothelial cancers. |
 | Banu Symington, MD, MACP, FASCO Medical oncologist at St. John’s Health and a longtime leader in rural oncology, Dr. Symington is admired for her commitment to improving access to cancer care in underserved regions. She has spearheaded education initiatives for community providers and contributed to the development of telemedicine-based oncology services. Her work has been pivotal in reducing geographic disparities in cancer treatment. |
 | Jennifer Leigh McQuade, MD, FASCO Assistant Professor at MD Anderson Cancer Center, Dr. McQuade is known for her pioneering research on the role of metabolism, the microbiome, and sex differences in melanoma. Her work on obesity and cancer immunotherapy outcomes has had significant implications for personalized cancer care. She is a strong advocate for physician-scientist training and career development. |
 | Umang Swami, MD, FASCO GI and GU oncology specialist at the Huntsman Cancer Institute, Dr. Swami is recognized for his contributions to early-phase clinical trials and biomarker-driven therapies in gastrointestinal cancers. He has led several innovative studies and is widely respected for his role in mentoring trainees and advocating for precision medicine in routine care. |
 | Eleonora Teplinsky, MD, FASCO Head of Breast Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care, Dr. Teplinsky is a prominent voice in breast cancer advocacy, clinical trial access, and patient education. She is also known for her impactful presence on social media, where she promotes science-based information and supports patient empowerment in oncology care. |
 | Emily Zaruhi Touloukian, DO, FASCO Dr. Touloukian is an independent community oncologist and the President and CEO of Coastal Cancer Center in Myrtle Beach, SC. In addition to being a dedicated physician, she is a strong advocate leading efforts to improve access to cancer care while providing compassionate, high-quality treatment to her patients. Her leadership and commitment to both clinical excellence and healthcare advocacy make her a powerful voice for patients and the oncology community alike. |
 | Jonathan C. Trent, MD, PhD, FASCO Director of the Sarcoma Medical Oncology Program at Sylvester Comprehensive Cancer Center, University of Miami, Dr. Trent is a globally respected authority on gastrointestinal stromal tumors (GIST) and sarcomas. His clinical trials and translational research have shaped current treatment paradigms, and he remains a key leader in sarcoma advocacy and education worldwide. |
 | Reginald Tucker-Seeley, ScD, FASCO Vice President of Health Equity at ZERO Prostate Cancer, Dr. Tucker-Seeley is a leading health disparities researcher whose work has focused on the social determinants of health in cancer care. His research has influenced national strategies to reduce inequities in cancer screening, treatment, and survivorship, particularly for men at risk for prostate cancer. |
 | Katherine Van Loon, MD, MPH, FASCO Director of the Global Cancer Program at UCSF Helen Diller Family Comprehensive Cancer Center, Dr. Van Loon is internationally recognized for her work in gastrointestinal cancers and global oncology. Her research addresses disparities in cancer outcomes and access to care, with a focus on implementing resource-adapted treatment strategies in low- and middle-income countries. |
 | Eddy Shih-Hsin Yang, MD, PhD, FASCO Chair of Radiation Oncology at the University of Mississippi Medical Center, Dr. Yang is a translational scientist and clinician known for his work on DNA repair, radiosensitization, and personalized radiation therapy. His research bridges molecular biology and clinical oncology, with a focus on breast and prostate cancers. He is a dedicated mentor and national leader in advancing precision radiation oncology. |
 | Oladapo O. Yeku, MD, PhD, FACP, FASCO Gynecologic medical oncologist at Massachusetts General Hospital and Harvard Medical School, Dr. Yeku is a leader in cellular immunotherapy and translational cancer research. His work on engineered T-cell therapies for ovarian and endometrial cancers is pushing the boundaries of innovation in solid tumor immunotherapy. He is also a champion for diversity in academic oncology and equitable trial participation. |
 | Marjorie Glass Zauderer, MD, MS, FACP, FASCO Co-Director of the Mesothelioma Program at Memorial Sloan Kettering Cancer Center, Dr. Zauderer is internationally known for her work in thoracic malignancies, particularly mesothelioma. Her leadership in early-phase and biomarker-driven clinical trials has expanded treatment options for patients with rare thoracic cancers. She also serves as a mentor and advocate for women in oncology research. |
 | Tian Zhang, MD, MHS, FASCO Associate Professor of Medicine at UT Southwestern Medical Center, Dr. Zhang is a rising leader in genitourinary oncology, particularly renal and bladder cancer clinical trials. She has made major contributions to defining the role of immunotherapy and biomarkers in advanced kidney cancer. Her collaborative work across cooperative groups continues to advance the field of personalized GU cancer care. |
 | Jeanny B. Aragon-Ching, MD, FACP, FASCO Associate Professor at George Washington University and clinical leader at the Inova Schar Cancer Institute, Dr. Aragon-Ching is widely recognized for her contributions to prostate and bladder cancer care. She has published extensively on systemic therapies and is actively involved in clinical research and professional society leadership. She is also a passionate advocate for improving oncology care in minority populations. |
 | Richard M. Ingram, MD, FASCO Medical oncologist at Cone Health Cancer Center in North Carolina, Dr. Ingram has championed community-based oncology research and practice transformation. He has served in leadership roles with ASCO’s Clinical Affairs Committee, helping shape quality standards and value-based care models. His dedication to advancing cancer care in non-academic settings has improved access and outcomes for thousands of patients. |
Stay tuned for more global oncology updates by OncoDaily.
Written by Nare Hovhannisyan, MD